Levodopa/Carbidopa/Entacapone Eg (Carbidopa, Entacapone, Levodopa)

Levodopa serves as a dopamine precursor that crosses the blood‑brain barrier. Carbidopa blocks peripheral conversion of levodopa to dopamine, increasing the amount that reaches the brain. Entacapone inhibits the COMT enzyme, prolonging levodopa's plasma half‑life and sustaining its central dopaminergic effect.

Dosing is individualized and must be determined by a qualified prescriber based on the patient's clinical condition, response, and tolerability. The healthcare professional will select the appropriate strength, frequency, and any dose adjustments needed over time.

The safety of Levodopa/Carbidopa/Entacapone during pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by the prescribing physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Compared with levodopa/carbidopa alone, the addition of entacapone extends levodopa's half‑life, reducing "off" periods and allowing more stable symptom control. Alternative COMT inhibitors (e.g., tolcapone) exist, but entacapone has a more favorable hepatic safety profile, making it a common choice for combination therapy.

Levodopa/Carbidopa/Entacapone tablets should be stored at ambient temperature, below 25 °C, in the original container to protect from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

The medication is taken orally, usually with food or a light snack to reduce gastrointestinal irritation. Tablets should be swallowed whole with a glass of water and not crushed, chewed, or split unless specifically instructed by the prescriber.

Serious adverse events include severe hypotension, hallucinations or psychosis, and dyskinesia that interferes with daily activities. Patients should seek immediate medical attention if they experience sudden drops in blood pressure, visual or auditory disturbances, or uncontrolled involuntary movements.

The combination is contraindicated in individuals with known hypersensitivity to levodopa, carbidopa, entacapone, or any excipients. It should also be avoided in patients with narrow‑angle glaucoma, severe hepatic impairment, or those currently taking non‑selective MA